Bevacizumab, a monoclonal antibody effective against VEGFA, may be a cheaper alternative for ranibizumab, but its use in the eye is not regulated by the FDA and is used off label to treat AMD, but its efficacy and safety is comparable with ranibizumab [35]. This evidence concerns the gene VEGFA and age-related macular degeneration.